Loading
A phase 1/2 trial of NKT2152 run by NiKang Therapeutics, Inc., terminated.
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma is a phase 1/2 interventional study registered as NCT05119335 by NiKang Therapeutics, Inc., with 120 participants enrolled, started 2021-10-26, primary completion reached 2025-08-22. Conditions recorded: ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Hypoxia, Renal Cell Carcinoma, Hypoxia Inducible Factor (HIF), HIF2α Inhibitor, Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha), Hypoxia Inducible Factor 2α (HIF-2α), Clear Cell. Interventions recorded: Oral NKT2152. Reason given for stopping: This study was terminated as a result of Sponsor portfolio reprioritization.
Shares NKT2152, NiKang Therapeutics, Clear cell renal cell carcinoma and the tag pipeline.
Shares NiKang Therapeutics and the tag pipeline.
Shares NiKang Therapeutics and the tag pipeline.
Shares NiKang Therapeutics and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares NiKang Therapeutics and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/